JP Morgan Chase
NAMS icon

JP Morgan Chase’s NewAmsterdam Pharma NAMS Stock Holding History

JP Morgan Chase’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.4M Buy
1,132,955
+248,727
+28% +$8.2M ﹤0.01% 1673
2026
Q1 		$25.9M Sell
884,228
-115,748
-12% -$3.77M ﹤0.01% 1867
2025
Q4 		$35.1M Sell
999,976
-302,522
-23% -$11M ﹤0.01% 1605
2025
Q3 		$37M Sell
1,302,498
-156,399
-11% -$3.75M ﹤0.01% 1616
2025
Q2 		$26.4M Buy
1,458,897
+467,579
+47% +$8.53M ﹤0.01% 1751
2025
Q1 		$20.3M Buy
991,318
+930,341
+1,526% +$20.7M ﹤0.01% 1919
2024
Q4 		$1.57M Buy
60,977
+38,626
+173% +$820K ﹤0.01% 4326
2024
Q3 		$371K Buy
22,351
+14,280
+177% +$247K ﹤0.01% 5096
2024
Q2 		$155K Buy
8,071
+3,752
+87% +$75.3K ﹤0.01% 5282
2024
Q1 		$102K Buy
+4,319
New +$87.7K ﹤0.01% 5667
2023
Q4 		– Sell
-2,622
Closed -$24.3K – 7748
2023
Q3 		$24.3K Sell
2,622
-8,841
-77% -$95.7K ﹤0.01% 6021
2023
Q2 		$136K Sell
11,463
-10,904
-49% -$145K ﹤0.01% 5306
2023
Q1 		$301K Buy
22,367
+21,265
+1,930% +$268K ﹤0.01% 4807
2022
Q4 		$12K Buy
+1,102
New +$11K ﹤0.01% 5998

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

JP Morgan Chase's NAMS Position: Q2 2026 in Review

JP Morgan Chase increased its NewAmsterdam Pharma (NAMS) stake by 28% in Q2 2026, buying an estimated $8.2M and bringing the position to 1,132,955 shares worth $38.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1673.

JP Morgan Chase first reported a position in NAMS in Q4 2022 and has held it in 14 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • JP Morgan Chase held 1,132,955 shares of NewAmsterdam Pharma worth $38.4M as of Q2 2026.
  • JP Morgan Chase bought 248,727 NewAmsterdam Pharma shares in Q2 2026, an estimated $8.2M.
  • NewAmsterdam Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1673 holding.
  • JP Morgan Chase first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 14 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.